AwesomeStocks Donât want emails from us anymore? Click [here]( to unsubscribe. Hello! New Alert: NanoViricides, Inc. (NYSE American: NNVC) NNVC is our new NYSE high volatility alert and a previous big winner. Following our last alert in May when NNVC was trading under 2.12, it consistently rallied afterwards, reaching a high last week of 3.59, gains of +69% in a month! Since this rally, NNVC has consolidated those gains, closing Friday at 1.90. Since our last update, over the past month, NNVC announced multiple developments. NNVC is a NYSE listed âdevelopment stage company that is creating special purpose nanomaterials for antiviral therapyâ. The Company's ânovel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle themâ. NNVCâs âlead drug candidate is NV-387 (drug product NV-CoV-2) for the treatment of RSV, COVID-19, Long COVID, Influenza, Bird Flu H5N1, and other respiratory viral infectionsâ. As the company further explains: - âNV-387 has successfully completed a Phase 1a/1b human clinical trial in healthy subjects with no reported adverse events even at the highest and repeated dosages.â The companyâs âother advanced candidate is NV-HHV-1 for the treatment of Shingles rash, HSV-1 "cold sores", and HSV-2 "genital ulcers"â. NNVC is also âdeveloping drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among othersâ. Importantly: âNanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel.â âNanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses.â Since our last update, in May, the company announced: âLethally RSV Infected Animals Orally Treated with NV-387 Showed Normal Lung Histology, Indicating Potential Cureâ As the company further explains, âthe strong antiviral activity of NV-387 against RSV/A2 is clearly demonstrated by lungs remaining normal and showing no infection-related damage, when treated orally with NV-387, in a lethal lung RSV infection animal model. The animals in only the NV-387 treated group survived completely, as previously reported. The complete survival and clear lungs indicate that NV-387 treatment completely protected the animals and could be potentially a cure for RSV infectionâ. Here are some of the comments from this press release: "These results clearly demonstrate that NV-387 oral treatment would be of great clinical value for protecting infants and children from RSV," said Anil R. Diwan, PhD, adding, "We are very pleased with these results and plan on advancing NV-387 for the treatment of RSV infection into clinical trials as soon as possible." Plus, the company announced: âNanoViricides Bolsters Partnership Efforts - Engages Aagami Inc.â As the company further explains: âThe Company is currently seeking licensing and partnering opportunities for its key asset, NV-387, and its key nanoviricides⢠platform technology. The Company has engaged Aagami, a small boutique firm, to help with these efforts for the regions of India and Japan, noting the firmâs strength and specialty in these regions for licensing and partnering endeavors.â Here are some of the comments from this press release: "Engaging Aagami gives a significant boost to our licensing and partnering efforts, while at the same time substantially freeing up our executives and staff to focus more strongly on further development of our multiple drugs and the nanoviricides platform through clinical trials," said Anil R. Diwan, PhD, President and Executive Chairman of the Company. In addition, the company also announced: âA First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and Moreâ As the company further explains in the press release: âNo matter how much a virus changes in the field, it uses the same "landing sites" in the host body to gain access to cells, attach to and then fuse into the cells, causing an infection. A drug using the same landing sites and acting as a "decoy" would remain effective against the virus even as the virus changes, because the host side does not change.â Importantly: âNV-387 is designed to employ such advanced "host-mimetic" technology, built into the nanoviricide⢠nanomedicine that is further designed to "look like a cell" to the virus.â âIn contrast, vaccines, antibodies and small chemical drugs all lose their effectiveness as the virus changes in the field. The virus is constantly changing due to various natural mechanisms such as mutations, recombinations, and/or re-assortments that are native to the virus lifecycle.â Here are some of the companyâs comments from this press release: "An antiviral agent with an extra-ordinarily broad spectrum of antiviral activity, coupled with strong safety, is a âholy grail' of antiviral medicines," said Anil R. Diwan, Ph.D., President and Executive Chairman of the Company, adding, "Our host-mimetic, direct-acting, nanoviricide⢠platform technology capable of destroying virus particles has made this possible, we believe. NV-387 is now ready for Phase II studies towards the goal of regulatory approvals worldwide." He further commented, "If and when approved, NV-387 could be as revolutionary an antiviral agent as penicillin was as an anti-bacterial agent." Two weeks ago, the company announced: âThe Sustained, Slow Declining, Blood Concentration Profile of NV-387 Enables Infrequent Dosing for Strong Antiviral Effectâ As the company states in the press release: - âThe utility of NV-387 is extremely broad, reminiscent of the utility of antibiotics.â In addition, last week, the company announced: âOrally Administered NV-387 Results in Ideal Flat Blood Concentration Profile for Sustained Antiviral Effectâ As the company further explains: âThe flat time profile of NV-387 indicates that even at very high dosings, its blood concentration is unlikely to result in unwanted side effects. Typical drugs result in a rapid rise in blood concentration of the drug in generally the first hour to a peak, thereafter rapidly exponentially decreasing to baseline in 3-6 hours. In order to ensure that the concentration of the drug is sufficiently high to provide antiviral effect at say 2-4 hours from dosing, the drug dose chosen would be relatively high, and can therefore result in a substantially greater drug concentration in the beginning, which can result in unwanted side effects. Therefore, a sustained, nearly flat drug concentration profile is highly sought-after.â Make sure to do your own due diligence. Sources: [PR1]( [PR2]( [PR3]( [PR4]( [PR5]( [PR6]( [Website]( [Chart]( Happy Trading! AwesomeStocks Note: We encourage all traders and investors to develop personal trading rules that you can follow and that work for you. Always protect your downside and note that we alert extremely volatile short-term opportunities. Before investing in securities, you should always consult with your financial, tax and legal advisor and never invest money you cannot afford to lose. DISCLAIMER You should read and understand this disclaimer in its entirety before joining the website or email/blog list of AwesomeStocks.com (the âPublisherâ). The information (collectively the âAdvertisementâ) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the senderâs phone number with the word STOP or HELP for help. The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at www.sec.gov; the Financial Industry Regulatory Authority (the "FINRA") at www.FINRA.org, and relevant State Securities Administrator website and the OTC Markets website at www.otcmarkets.com. The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at www.sec.gov/consumer/cyberfr.htm, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete. The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete. Owners and operators of the Publisher have been compensated ten thousand dollars by bank wire transfer on 6/14/24 for the distribution of this advertisement about NNVC dated 6/17/24. Previously, owners and operators of the Publisher have been compensated ten thousand dollars by bank wire transfer on 5/15/24 for the distribution of a prior advertisement about NNVC. Previously, owners and operators of the Publisher have been compensated ten thousand dollars by bank wire transfer on 5/8/24 for the distribution of a prior advertisement about NNVC. Previously, owners and operators of the Publisher have been compensated ten thousand dollars by bank wire transfer on 6/28/23 for the distribution of a prior advertisement about NNVC. Prior to the past year, at the time of publication, we disclosed our compensation for the distribution of advertisements about NNVC. The Publisher and its owners and operators hold no stocks or bonds in companies discussed in the Advertisement. Owners and operators of the Publisher own several newsletters, therefore you may receive multiple publications and emails featuring companies at different or the same time. You are receiving this report/release because you subscribed to receive it at our website or through a third-party site. All our newsletters include an "unsubscribe" link, and you can remove yourself at any time from our newsletters by clicking on that "unsubscribe" link. You can also contact us at info@AwesomeStocks.com to change your information at any time. By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link: www.AwesomeStocks.com/Disclaimer and www.AwesomeStocks.com/Privacy-Policy By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink. Our records indicate that {EMAIL} requested and confirmed to be added to AwesomeStocks.com on March 5, 2023. [Click Here To Unsubscribe]( 6020 Bent Pine Dr
Orlando Florida 32822
USA [Unsubscribe]( | [Change Subscriber Options](